Ann: Strategic Review Outcome and Program Updates, page-16

I think downside on the Agitation is way bigger than any upside.

I cannot stress enough how dodgy I found the dot point on Agitation yesterday - at full enrollment he would have known: total number of trial patients, whether there were any adverse reactions & expected date for the read out. He didn't give any of that.

Yesterday's announcement struck me as meeting minutes that his assistant took at the board meeting & he thought "Yeah that'll do".

D'Snooza needs to go - he seems completely unmotivated, disinterested in shareholders, the company.